This study aims to determine the safety and maximum tolerated dose (MTD) of YMN-136 vaccine through a dose escalation trial, and to investigate whether YMN-136 vaccine can assist in the treatment of patients with metastatic colorectal cancer.
Voluntarily sign the informed consent form, be able to understand and agree to follow the prescribed research procedures and visits;
Aged 18-75 years, both male and female are eligible;
Histologically confirmed unresectable advanced colorectal adenocarcinoma;
First-line treatment: Chemotherapy combined with targeted drugs (such as FOLFOX/FOLFIRI combined with anti-EGFR cetuximab or anti-VEGF bevacizumab).
Patients with extensive peritoneal metastasis or intestinal obstruction; patients with uncontrollable pleural effusion, pericardial effusion, or ascites requiring repeated drainage;
Patients known to be allergic to the components of the investigational drug (such as lipid nanoparticles, RNA vectors) or similar drugs;
Patients who have previously received vaccine therapy;
Patients who have received chemotherapy, targeted therapy, or immunotherapy within 4 weeks before the first dose;